Intensity Therapeutics Inc
INTS0.410USD
-0.007-1.75%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
20.14MMarket Cap
LossP/E TTM
More Details of Intensity Therapeutics Inc Company
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Intensity Therapeutics Inc Info
Ticker SymbolINTS
Company nameIntensity Therapeutics Inc
IPO dateJun 30, 2023
CEOBender (Lewis H)
Number of employees5
Security typeOrdinary Share
Fiscal year-endJun 30
Address1 Enterprise Drive, Suite 430
CitySHELTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code06484
Phone12032217381
Websitehttps://www.intensitytherapeutics.com
Ticker SymbolINTS
IPO dateJun 30, 2023
CEOBender (Lewis H)
Company Executives of Intensity Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Lewis H. (Lew) Bender
Mr. Lewis H. (Lew) Bender
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.02M
--
Mr. Joseph (Joe) Talamo, CPA
Mr. Joseph (Joe) Talamo, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. John Wesolowski, CPA
Mr. John Wesolowski, CPA
Principal Accounting Officer, Controller
Principal Accounting Officer, Controller
--
--
Mr. Daniel J. Donovan
Mr. Daniel J. Donovan
Independent Director
Independent Director
--
--
Mr. Thomas I. H. Dubin, J.D.
Mr. Thomas I. H. Dubin, J.D.
Independent Director
Independent Director
--
--
Dr. Mark A. Goldberg, M.D.
Dr. Mark A. Goldberg, M.D.
Independent Director
Independent Director
--
--
Dr. Emer Leahy, Ph.D.
Dr. Emer Leahy, Ph.D.
Independent Director
Independent Director
--
--
Mr. Justin Kulik
Mr. Justin Kulik
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Lewis H. (Lew) Bender
Mr. Lewis H. (Lew) Bender
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.02M
--
Mr. Joseph (Joe) Talamo, CPA
Mr. Joseph (Joe) Talamo, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. John Wesolowski, CPA
Mr. John Wesolowski, CPA
Principal Accounting Officer, Controller
Principal Accounting Officer, Controller
--
--
Mr. Daniel J. Donovan
Mr. Daniel J. Donovan
Independent Director
Independent Director
--
--
Mr. Thomas I. H. Dubin, J.D.
Mr. Thomas I. H. Dubin, J.D.
Independent Director
Independent Director
--
--
Dr. Mark A. Goldberg, M.D.
Dr. Mark A. Goldberg, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Batterson (Leonard A.)
4.08%
Bender (Lewis H)
3.36%
Sapient Capital LLC
1.63%
LFP Management LLC
1.16%
Sentinus, LLC
0.80%
Other
88.97%
Shareholders
Shareholders
Proportion
Batterson (Leonard A.)
4.08%
Bender (Lewis H)
3.36%
Sapient Capital LLC
1.63%
LFP Management LLC
1.16%
Sentinus, LLC
0.80%
Other
88.97%
Shareholder Types
Shareholders
Proportion
Individual Investor
7.59%
Investment Advisor
3.88%
Corporation
1.16%
Investment Advisor/Hedge Fund
0.74%
Research Firm
0.18%
Hedge Fund
0.16%
Other
86.29%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
44
2.24M
3.74%
-370.85K
2025Q2
43
8.94M
19.43%
+516.61K
2025Q1
42
9.10M
50.86%
+683.32K
2024Q4
40
9.22M
61.01%
+1.99M
2024Q3
37
8.23M
55.55%
+1.09M
2024Q2
36
8.17M
55.24%
+1.09M
2024Q1
32
7.00M
51.04%
+4.23M
2023Q4
26
2.71M
19.83%
+202.03K
2023Q3
17
2.48M
18.80%
+269.88K
2023Q2
6
2.21M
16.84%
+28.56K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Batterson (Leonard A.)
2.45M
5%
--
--
Aug 31, 2025
Bender (Lewis H)
2.02M
4.12%
--
--
Aug 31, 2025
Sapient Capital LLC
976.80K
1.99%
--
--
Jun 30, 2025
LFP Management LLC
696.87K
1.42%
+696.87K
--
May 31, 2024
Sentinus, LLC
199.32K
0.41%
+172.01K
+629.99%
Jun 30, 2025
Geode Capital Management, L.L.C.
72.81K
0.15%
-4.67K
-6.03%
Jun 30, 2025
The Vanguard Group, Inc.
40.59K
0.08%
-190.07K
-82.40%
Jun 30, 2025
Mesirow Financial Investment Management, Inc.
110.00K
0.22%
+70.00K
+175.00%
Jun 30, 2025
Brown Advisory
130.07K
0.27%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Intensity Therapeutics Inc?
The top five shareholders of Intensity Therapeutics Inc are:
Batterson (Leonard A.) holds 2.45M shares, accounting for 5.00% of the total shares.
Bender (Lewis H) holds 2.02M shares, accounting for 4.12% of the total shares.
Sapient Capital LLC holds 976.80K shares, accounting for 1.99% of the total shares.
LFP Management LLC holds 696.87K shares, accounting for 1.42% of the total shares.
Sentinus, LLC holds 199.32K shares, accounting for 0.41% of the total shares.
Batterson (Leonard A.) holds 2.45M shares, accounting for 5.00% of the total shares.
Bender (Lewis H) holds 2.02M shares, accounting for 4.12% of the total shares.
Sapient Capital LLC holds 976.80K shares, accounting for 1.99% of the total shares.
LFP Management LLC holds 696.87K shares, accounting for 1.42% of the total shares.
Sentinus, LLC holds 199.32K shares, accounting for 0.41% of the total shares.
What are the top three shareholder types of Intensity Therapeutics Inc?
The top three shareholder types of Intensity Therapeutics Inc are:
Batterson (Leonard A.)
Bender (Lewis H)
Sapient Capital LLC
Batterson (Leonard A.)
Bender (Lewis H)
Sapient Capital LLC
How many institutions hold shares of Intensity Therapeutics Inc (INTS)?
As of 2025Q3, 44 institutions hold shares of Intensity Therapeutics Inc, with a combined market value of approximately 2.24M, accounting for 3.74% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -15.69%.
What is the biggest source of revenue for Intensity Therapeutics Inc?
In --, the -- business generated the highest revenue for Intensity Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
